Medscape is available in 5 Language Editions – Choose your Edition here.


Elective Abortion Follow-up

  • Author: Frances E Casey, MD, MPH; Chief Editor: Michel E Rivlin, MD  more...
Updated: Feb 29, 2016

Further Outpatient Care

Postoperative care of a patient after surgical abortion includes the following:

  • Observe patients for 30 minutes, checking for abdominal pain and unusual bleeding and observing vital signs. Immediate cervical stenosis with occlusion and hematometra can be treated by administration of oral or buccal misoprostol.
  • Anti-D immunoglobulin should be administered on the day of the procedure to patients who are Rh-negative.
  • Patients selecting immediate intrauterine device (IUD) insertion, depot-medroxyprogesterone acetate (DMPA), or contraceptive implant may begin their contraceptive on this day.
  • Postoperative appointments are usually 1-3 weeks after the procedure and are important to ensure timely involution, confirm the pregnancy termination has been completed, evaluate the patient for medical complications, offer continuing contraceptive care, and evaluate psychological status.
  • Patients who are seen at 1-3 weeks after a medical abortion have completion of the process documented by ultrasonography. The endometrial echo will still show a fairly thick decidual lining, but no gestational sac should be seen. Reaspiration should be based on patient symptoms of ongoing heavy bleeding or infection rather than thickness of the endometrium. If a pregnancy test is used, it should be the less sensitive test. Sensitive urine pregnancy tests can remain positive for many weeks. If a pregnancy test is negative, the ultrasound examination can probably be safely avoided. Patients who fail to see a provider should be urged to perform a pregnancy test in follow up.
  • Postoperatively, patients should be given instructions to contact their providers if they have severe pain, have a fever of 100.4°F or higher, or soak through more than 2 pads per hour or more than 12 pads in 24 hours. Patients may take NSAIDs for pain relief, such as ibuprofen or naproxen.
  • Provide patients with emergency contact numbers and instructions regarding where to go if they have an emergency and cannot reach the provider.
  • Patients may bleed very little, if at all, if they were very early in gestation, but the most common bleeding pattern is bleeding the day of the procedure, then not much until the fifth postoperative day, when heavier cramping and clotting occurs.
  • Patients should not have intercourse until a week post procedure and then it should be when they feel ready.
  • With antibiotic use as prophylaxis, postabortion infection rates in most population groups should be less than 1-2%. Antibiotic use for the procedure is usually limited to the day of the procedure or a 2- to 3-day course. The antibiotics used are typically broad in spectrum, and most centers use doxycycline at 100 mg bid, with azithromycin for those who are allergic. If bacterial vaginosis is discovered, then the use of Flagyl at 500 mg bid or Cleocin at 300 mg bid PO is selected. Some providers with caseloads of patients who come from far distances and are difficult to locate postoperatively may opt to administer longer antibiotic courses to cover the event of a positive chlamydia or gonorrhea test result after the patient has left the facility and either cannot or does not want to be contacted.
  • Most oral contraceptive pills can be started the day of the procedure or the following Sunday. IUDs or implants can be inserted that day or with the next menstrual period. DMPA shots can be given that day or up to 5 days later.

Regarding uterine perforation, if the patient had a fundal perforation with no suction applied, then observation for a few hours and evaluation of Hb levels is the standard of care.

When evaluating for acute abdominal pain postabortion, consider acute hematometra, retained products of conception, pelvic infection, or perforation with or without bowel involvement. In patients with prior cesarean deliveries, consider abnormal placentation.

Postoperative bleeding after a surgical abortion is different in timing, amount, and sequence to the bleeding post medical abortion. The amount and duration depends upon the gestational age of the pregnancy terminated.


Further Inpatient Care

Note the following:

  • Termination of pregnancy virtually never requires inpatient treatment. If the patient has a medical condition that requires hospitalization, then the indications for hospitalization for that condition should be followed. In cases of placenta previa, the patient may have to be observed in the hospital if cervical preparation is being undertaken (laminaria insertion).
  • Patients with a medical complication of pregnancy termination, such as a perforation, are cared for according to the treatment necessary. Initial evaluation with serial hemoglobin testing, attention to vital signs such as low blood pressure level and/or tachycardia, and repeat ultrasonography can help determine the diagnosis. A patient with temperature elevation either after laminaria insertion or immediately in the postoperative period should be evaluated for dehydration, medication reaction, infection, and sepsis. Evaluation of uterine contents can also help determine the completeness of the procedure.
  • Patients who have a fundal perforation, with an instrument that is not connected to suction, may require observation, but this is usually not necessary.
  • Patients with perforations that may be related to bowel injury may need exploratory surgery via laparoscopy (with an extremely experienced laparoscopist) or an exploratory laparotomy. Radiologic studies showing an unusual fluid collection in the pelvis, a broad-ligament hematoma, or evidence of free air increase the suspicion of a perforation. If these procedures are used, hospitalization may be required for 1-5 days to manage the usual postoperative course.
  • Antibiotic prophylaxis is recommended for any additional surgery, with broad-spectrum antibiotic coverage administered over at least 24 hours.

Inpatient & Outpatient Medications

The following are medications used to manage patients undergoing an elective abortion:

  • Antibiotic therapy
  • Uterotonics
  • Analgesia
  • Antiemetics
  • Antianxiolytics
  • Oral contraceptives
  • Long-term steroid contraception


Effective contraception is the only reasonable strategy for abortion prevention.

Studies show that providing long-acting reversible contraceptives (LARC)—which would include the copper T intrauterine device (IUD), the levonorgestrel-releasing IUD (LNG-IUD), and the single-rod subdermal implant—provide the best statistical prevention of repeat abortion as well as being a possible contraceptive alternative for the largest number of patients and being cost effective in the long term.[26]



Complications of surgical abortion vary with the technique used, training of the provider, and the gestational age of the pregnancy. In general, the more advanced the gestational age at abortion, the higher the complication rate, and the more invasive the operative procedure, the higher the complication rate.

First-trimester abortion

Complication rates are low: 0.071% for hospitalization and 0.846% for minor complications. Abortion complications requiring hospitalization include incomplete abortion (0.028%), sepsis (0.021%), uterine perforation (0.009%), vaginal bleeding (0.007%), inability to abort (0.003%), and combined pregnancy (0.002%). Minor abortion complications include infection (0.46%), repeat suction (0.18%), cervical stenosis (0.016%), cervical tear (0.01%), seizure (0.004%), and underestimate of dates (0.006%).

Manual vacuum aspiration has the following complication rates: infection, 0.7%; perforation, 0.05%; retained POC, 0.5%; and repeat aspiration, 0.5-0.25%.

Second-trimester abortion

In D&E and D&X, the skill and experience of the physician are the most important factors in maintaining a low complication rate. Complication rates are low but increase with gestational age. Abortion complications requiring hospitalization include perforation, hemorrhage, infection, retained POC, and inability to complete abortion. Overall rates of hospitalization are 0.6% at 13 weeks of gestation and 1.4% at 20-21 weeks of gestation. Coagulopathy is a rare complication in D&E, occurring in 191 of 100,000 cases.

Avoid complications by obtaining adequate cervical dilatation through using passive dilators in abortions at 14 weeks of gestation and longer and by using double placement of passive dilators at longer than 20 weeks of gestation. Have appropriate instruments available for morbidly obese patients because standard instruments may not be long enough. Match the surgeon's skill and experience to the gestational age of the pregnancy to be terminated. Choose an inpatient setting for patients with severe medical conditions, anemia, placenta praevia (or other abnormal placentation), pelvic masses or large leiomyomas, or vein problems (eg, no intravenous access).

Uterine hemorrhage

Hemorrhage can be caused by atony, retained products, or perforation. Hemorrhage has been defined in a variety of ways, and the need for transfusion is exceedingly rare. If uterine hemorrhage rates include hemorrhage immediately postabortion, uterine atony rates of hemorrhage are as low as 5%. Initial hemorrhage should be evaluated by ensuring complete uterine evacuation.

General anesthesia increases the risk of atony. Blood loss of more than 300 mL in the first trimester is considered excessive. The next steps are typically medical in nature, ie, the use of intramuscular Methergine at 0.2 mg, the use of misoprostol 800 mcg placed rectally. Hemabate is also helpful. Treatment also can include uterine massage medications, removal of retained products, and repair of perforation as indicated. In the past, uterine packing has been used, but this can be accomplished effectively with the intrauterine inflation of a Foley balloon. Balloons of 5 mL can be inflated with 30 mL, or 30-mL balloons can be inflated with up to almost 100 mL of sterile saline. The inflation should correlate with uterine size. Now a Bakri Balloon designed for post abortion or postpartum hemorrhage can be used.

Uterine artery embolization can be used if placenta accreta is encountered, but very few of these procedures have been performed and statistical success rates are impossible to evaluate. If ineffective, hysterectomy should be performed as a life-saving measure.

Damage to cervix

The risk of cervical damage is increased with previous surgery to the cervix or laceration. Damage can be associated with forceful dilation with metal dilators and may be associated with damage to cervical vessels, with hemorrhage and parametrial hematoma formation. Repair damage using a transvaginal approach or laparoscopy/ laparotomy. Prevent damage by avoiding forceful dilation. Passively dilate the cervix using passive dilators and/or prostaglandin analogues. Delay the procedure if adequate dilation is not achieved.

Uterine perforation

Perforation has been estimated to occur in 1 per 250 cases. They are usually fundal and recognized by the provider at the time of the procedure. In a study by Pridmore and Chambers of 13,907 women who underwent outpatient termination of pregnancy, the perforation rate was 0.05% and, in the second trimester, ie, procedures from 13-20 weeks, the perforation rate was 0.32%.[27]

Risk factors for perforation are previous terminations of pregnancy, lower-segment cesarean deliveries, and loop electrosurgical excision procedures of the cervix. The common denominator is thought to be scarring of the internal cervical os.

Fundal perforations only require observation. If the extent of the perforation cannot be determined, if the patient is medically unstable, if the suction was applied at the time of the perforation, or if bowel or fat content was obtained by forceps at the time of a perforation, surgical evaluation of the patient is necessary. The surgical evaluation may be performed by an experienced laparoscopist or by laparotomy.

Perforation can occur with sound, dilators, curette, suction tip, forceps, or passive dilators. Increased risk is associated with previous surgery or laceration involving the cervix, previous uterine surgery, and grand multiparity. In the first trimester, most perforations are in the body of the uterus. Perforation can be recognized when an instrument passes endlessly, heavy or persistent vaginal bleeding occurs, signs of peritoneal irritation appear, or fat or other tissue appears in the specimen. If perforation is made with the sound or dilator, stop the procedure and observe the patient for a minimum of 1 hour. Antibiotic prophylaxis and ultrasonography are options. Reschedule the procedure to be performed in 2-3 weeks. If perforation occurs with suction tip or curette, stop the procedure. Options include observation if the patient is stable and the abortion is complete, laparoscopy if hemorrhage is suspected or the abortion is incomplete, and laparotomy if the patient is unstable.

Retained products of conception

Evaluation of the obtained products of conception at the time of abortion and postabortion uterine scanning have reduced the retained products of conception rate to less than 1% of cases. In one series reported by Hakim, Tovell, and Burnhill of 170,000 cases, only 0.5% incidence occurred in the first trimester.[28] In cases of second-trimester abortions, retained tissue rates are even lower, with rates of 0.2% according to Peterson and 0.5% according to Kafrissen et al.[29]

Cases of delayed bleeding, even after a normal cycle, have been reported. Dilatation and curettage or hysteroscopy are necessary if bleeding is brisker or if the amount of tissue is determined by sonographic evaluation to warrant more extensive procedures.

Endometritis and pelvic inflammatory disease

Infections postabortion are rare, occurring in fewer than 1% of cases. These are usually due to preexisting infections, such as bacterial vaginosis, cervicitis or salpingitis, or a failure of antibiotic prophylaxis.

Fever greater than 102°F (39°C) within 72 hours of the abortion should be considered septic abortion due to retained products. Treatment requires reaspiration followed by intravenous antibiotics (cefoxitin, clindamycin, chloramphenicol, cephalosporin with ampicillin, or penicillinase-resistant penicillin). Fever less than 102°F (39°C) should be treated with reaspiration and oral antibiotics (doxycycline 100 mg bid for 10 d).

The usual criteria should be used for the diagnosis of pelvic inflammatory disease (PID). The Centers for Disease Control and Prevention provides treatment guidelines as well as self-study and ready-to-use modules for clinicians at their Pelvic Inflammatory Disease (PID) Treatment Webpage.

Fatal toxic shock

Rapidly progressing toxic shock due to the endotoxins produced by Clostridia species bacteria has been reported 7 times (for a rate of 1 per 750,000).

Coexistent ectopic pregnancy

Residual positive hCG titers are not uncommon, and clinicians need to be vigilant in their evaluation of persistent positive pregnancy test results to avoid missing an ectopic pregnancy.

Pelvic ultrasonography is the most helpful tool. The presence of significant tenderness during the postoperative examination, a history of continued pain, and the elevation or plateau of hCG titers should raise concern. Coexistent intrauterine and extrauterine pregnancies are observed only in extremely rare cases.

Asherman syndrome

Postabortion uterine synechiae (or adhesions) that can obliterate part or all of the endometrial cavity have been reported. This is thought to be more likely secondary to endometritis than the instrumentation of the uterus, but sharp curetting after the abortion procedure should be avoided to avoid denuding the basal layer of the endometrium.

The diagnosis is made based on hysteroscopy or hysterosalpingogram findings in a patient who presents with postabortion amenorrhea.

Delayed sequelae

Abortion-related hemorrhage due to retained tissue can occur up to several weeks after the procedure. In general, blood loss in excess of that of a normal menstrual period is considered significant and should prompt reaspiration.

Few long-term sequelae of abortions have been documented. Both studies of first trimester surgical and medical abortion found that risks of ectopic pregnancies and spontaneous abortions in future pregnancies were not increased. Some studies have suggested an association between induced abortion and subsequent preterm birth and low birth weight.  However, these studies have been retrospective and unable to adequately adjust for confounders also contributing to these outcomes. Although a syndrome of posttraumatic stress has been reported, the literature has not been able to separate the stressors of the patient's social situation that lead to the abortion from the abortion procedure itself.

Although initial studies indicated a greater risk of breast cancer with elective termination than with term birth, a prospective cohort study indicates that no link exists between induced abortion and breast cancer. A prospective study (the Nurses' Health Study II) examined the association between induced and spontaneous abortion and the incidence of breast cancer. Most of the early data has been refuted.

Psychologic consequences of abortion

Generally, the psychological health of the abortion patient parallels her psychologic health prior to seeking an abortion. If the woman needed to have the abortion in secrecy, then long-term psychologic sequelae, such as intrusive thoughts, are more common.

Many studies have actually demonstrated improved psychological well-being after abortion. For the studies that have shown this, the improvement in psychological health is suggested to be more reflective of the patient dealing with the social issues that led her to select abortion.

Sometimes, confusion over normal emotions, such as sadness and grief versus psychological illnesses (eg, depression), seems to occur. The most common feeling experienced after an abortion is that of relief and confidence in the decision. Few women may experience feelings of grief and guilt postabortion, and these feelings usually pass within days to weeks in most cases and do not lead to psychological sequelae. One study demonstrated that the risk for serious psychiatric illness postabortion was 1%, whereas with live birth it was 10%. Considering that more than 1.5 million abortions are performed in the United States each year, if an epidemic of psychiatric sequelae due to the procedure occurred, it would be observed by now.

Many confounding factors are involved in a women's emotional status during the time of her abortion. Relationships, religion, age, social support, and previous psychological stability all play a part.

An entirely new set of circumstances and feelings exist in cases of rape and incest. These are often psychologically complex situations and unique to each case.

Providers can help women through abortions by presenting options and explaining the procedures. Counseling with a trained professional occurs before the abortion. This is a good time to identify factors that might lead to a patient having troubling feelings after the abortion. Some factors are low self-esteem, preexisting or past psychological illness, lack of emotional support, and past childhood sexual abuse. The counselor can then confront these issues before the procedure and help the patient assess specific needs and improve coping strategies.



Fertility is not impaired. Prognosis is excellent.


Patient Education

Give patients information about abortion and postabortion care. Educate patients about birth control options, and discuss when to start birth control postabortion.

Because most terminations of pregnancies in the United States are performed on unintended pregnancies, counseling regarding fertility and contraceptive management are mandatory. In 83% of women, ovulation occurs in the first menstrual cycle postabortion. In first-trimester abortions, contraception should be initiated immediately postoperatively. Intrauterine devices (IUDs) can be safely inserted at the time of the abortion procedure.

For patient education resources, see Pregnancy Center as well as Abortion, Miscarriage, and Dilation and Curettage (D&C).

Contributor Information and Disclosures

Frances E Casey, MD, MPH Director of Family Planning Services, Department of Obstetrics and Gynecology, VCU Medical Center

Frances E Casey, MD, MPH is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Reproductive Health Professionals, Society of Family Planning, National Abortion Federation, Physicians for Reproductive Health

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

A David Barnes, MD, MPH, PhD, FACOG Consulting Staff, Department of Obstetrics and Gynecology, Mammoth Hospital (Mammoth Lakes, CA), Pioneer Valley Hospital (Salt Lake City, UT), Warren General Hospital (Warren, PA), and Mountain West Hospital (Tooele, UT)

A David Barnes, MD, MPH, PhD, FACOG is a member of the following medical societies: American College of Forensic Examiners Institute, American College of Obstetricians and Gynecologists, Association of Military Surgeons of the US, American Medical Association, Utah Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Michel E Rivlin, MD Former Professor, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine

Michel E Rivlin, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Mississippi State Medical Association, Royal College of Surgeons of Edinburgh, Royal College of Obstetricians and Gynaecologists

Disclosure: Nothing to disclose.

Additional Contributors

Steven David Spandorfer, MD Assistant Professor, Department of Obstetrics and Gynecology, New York Presbyterian Hospital, Weill Cornell Medical College

Steven David Spandorfer, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine, Endocrine Society

Disclosure: Nothing to disclose.


Suzanne R Trupin, MD, FACOG Clinical Professor, Department of Obstetrics and Gynecology, University of Illinois College of Medicine at Urbana-Champaign; CEO and Owner, Women's Health Practice; CEO and Owner, Hada Cosmetic Medicine and Midwest Surgical Center

Suzanne R Trupin, MD, FACOG is a member of the following medical societies: American Association of Gynecologic Laparoscopists, American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, American Medical Association, Association of Reproductive Health Professionals, International Society for Clinical Densitometry, and North American Menopause Society

Disclosure: Nothing to disclose.

  1. Mikolajczak M, Bilewicz M. Foetus or child? Abortion discourse and attributions of humanness. Br J Soc Psychol. 2014 Nov 24. [Medline].

  2. Raymond EG, Grimes DA. The comparative safety of legal induced abortion and childbirth in the United States. Obstet Gynecol. 2012 Feb. 119(2 Pt 1):215-9. [Medline].

  3. Stulberg DB, Dude AM, Dahlquist I, Curlin FA. Abortion provision among practicing obstetrician-gynecologists. Obstet Gynecol. 2011 Sep. 118(3):609-14. [Medline].

  4. Bridges KM. When pregnancy is an injury: rape, law, and culture. Stanford Law Rev. 2013 Mar. 65(3):457-516. [Medline].

  5. Turk JK, Preskill F, Landy U, Rocca CH, Steinauer JE. Availability and characteristics of abortion training in US ob-gyn residency programs: a national survey. Contraception. 2014 Apr. 89(4):271-7. [Medline].

  6. Shanahan MA, Metheny WP, Star J, Peipert JF. Induced abortion. Physician training and practice patterns. J Reprod Med. 1999 May. 44(5):428-32. [Medline].

  7. Joffe C. The politicization of abortion and the evolution of abortion counseling. Am J Public Health. 2013 Jan. 103(1):57-65. [Medline].

  8. Cunningham GF, MacDonald PC, Gant NF. Abortion. Williams Obstetrics. 19th ed. 1993. 661-90.

  9. Induced Abortion in the United States. Guttmacher Institute. Available at July 2014; Accessed: February 29, 2015.

  10. Chasen ST, Kalish RB, Gupta M, Kaufman JE, Rashbaum WK, Chervenak FA. Dilation and evacuation at >or=20 weeks: comparison of operative techniques. Am J Obstet Gynecol. 2004 May. 190(5):1180-3. [Medline].

  11. Bryant AG, Grimes DA, Garrett JM, Stuart GS. Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation. Obstet Gynecol. 2011 Apr. 117(4):788-92. [Medline].

  12. Borgatta L, Kapp N. Clinical guidelines. Labor induction abortion in the second trimester. Contraception. 2011 Jul. 84(1):4-18. [Medline].

  13. Kahn JG, Becker BJ, MacIsaa L, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000 Jan. 61(1):29-40. [Medline].

  14. Koenig JD, Tapias MP, Hoff T, Stewart FH. Are US health professionals likely to prescribe mifepristone or methotrexate?. J Am Med Womens Assoc. 2000. 55(3 Suppl):155-60. [Medline].

  15. Clark W, Bracken H, Tanenhaus J, Schweikert S, Lichtenberg ES, Winikoff B. Alternatives to a routine follow-up visit for early medical abortion. Obstet Gynecol. 2010 Feb. 115(2 Pt 1):264-72. [Medline].

  16. Jones RK, Finer LB, Singh S. Characteristics of U.S. Abortion Patients, 2008. New York: Guttmacher Institute; 2010.

  17. Hayes JL, Achilles SL, Creinin MD, Reeves MF. Outcomes of medical abortion through 63 days in women with twin gestations. Contraception. 2011 Nov. 84(5):505-7. [Medline].

  18. Kornfield SL, Geller PA. Mental health outcomes of abortion and its alternatives: implications for future policy. Womens Health Issues. 2010 Mar-Apr. 20(2):92-5. [Medline].

  19. Ngoc NT, Shochet T, Raghavan S, et al. Mifepristone and misoprostol compared with misoprostol alone for second-trimester abortion: a randomized controlled trial. Obstet Gynecol. 2011 Sep. 118(3):601-8. [Medline].

  20. Grossman D, Grindlay K, Buchacker T, Lane K, Blanchard K. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol. 2011 Aug. 118(2 Pt 1):296-303. [Medline].

  21. Mifeprex (misoprostol) [package insert]. New York, NY: Danco Laboratories, LCC. March 2016. Available at [Full Text].

  22. Dickinson JE, Doherty DA. Optimization of third-stage management after second-trimester medical pregnancy termination. Am J Obstet Gynecol. 2009 Sep. 201(3):303.e1-7. [Medline].

  23. Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev. 2011 Jan 19. 1:CD005216. [Medline].

  24. Challis D, Gratacos E, Deprest JA. Cord occlusion techniques for selective termination in monochorionic twins. J Perinat Med. 1999. 27(5):327-38. [Medline].

  25. Edlow AG, Hou MY, Maurer R, Benson C, Delli-Bovi L, Goldberg AB. Uterine evacuation for second-trimester fetal death and maternal morbidity. Obstet Gynecol. 2011 Feb. 117(2 Pt 1):307-16. [Medline].

  26. Thompson KM, Speidel JJ, Saporta V, Waxman NJ, Harper CC. Contraceptive policies affect post-abortion provision of long-acting reversible contraception. Contraception. 2011 Jan. 83(1):41-7. [Medline].

  27. Pridmore BR, Chambers DG. Uterine perforation during surgical abortion: a review of diagnosis, management and prevention. Aust N Z J Obstet Gynaecol. 1999 Aug. 39(3):349-53. [Medline].

  28. Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. Obstet Gynecol. 1990 Jul. 76(1):129-35. [Medline].

  29. Kafrissen ME, Barke MW, Workman P, Schulz KF, Grimes DA. Coagulopathy and induced abortion methods: rates and relative risks. Am J Obstet Gynecol. 1983 Oct 1. 147(3):344-5. [Medline].

  30. Perry KG Jr, Rinehart BK, Terrone DA, Martin RW, May WL, Roberts WE. Second-trimester uterine evacuation: A comparison of intra-amniotic (15S)-15-methyl-prostaglandin F2alpha and intravaginal misoprostol. Am J Obstet Gynecol. 1999 Nov. 181(5 Pt 1):1057-61. [Medline].

  31. Kuppermann M, Nakagawa S, Cohen SR, et al. Attitudes toward prenatal testing and pregnancy termination among a diverse population of parents of children with intellectual disabilities. Prenat Diagn. 2011 Dec. 31(13):1251-8. [Medline].

  32. Grimes DA. Estimation of pregnancy-related mortality risk by pregnancy outcome, United States, 1991 to 1999. Am J Obstet Gynecol. 2006 Jan. 194(1):92-4. [Medline].

  33. Zhou W, Sorensen HT, Olsen J. Induced abortion and subsequent pregnancy duration. Obstet Gynecol. 1999 Dec. 94(6):948-53. [Medline].

  34. Hendricks MS, Chow YH, Bhagavath B, Singh K. Previous cesarean section and abortion as risk factors for developing placenta previa. J Obstet Gynaecol Res. 1999 Apr. 25(2):137-42. [Medline].

  35. Eras JL, Saftlas AF, Triche E, Hsu CD, Risch HA, Bracken MB. Abortion and its effect on risk of preeclampsia and transient hypertension. Epidemiology. 2000 Jan. 11(1):36-43. [Medline].

  36. Acharya PS, Gluckman SJ. Bacteremia following placement of intracervical laminaria tents. Clin Infect Dis. 1999 Sep. 29(3):695-7. [Medline].

  37. ACOG. ACOG practice bulletin. Clinical management guidelines of obstetrician-gynecologists. Number 67, October 2005. Medical management of abortion. Obstet Gynecol. 2005 Oct. 106(4):871-82. [Medline].

  38. ACOG. American College of Obstetricians and Gynecologists. Methods of Midtrimester Abortion. ACOG Technical Bulletin. 1987. 109:602-05.

  39. ACOG Compendium of Selected Publications. American College of Obstetricians and Gynecologists. Abortion Policy. 2005. 865-867.

  40. Aiyer AN, Ruiz G, Steinman A, Ho GY. Influence of physician attitudes on willingness to perform abortion. Obstet Gynecol. 1999 Apr. 93(4):576-80. [Medline].

  41. Ashok PW, Templeton A. Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. Br J Obstet Gynaecol. 1999 Jul. 106(7):706-10. [Medline].

  42. Baird DT. Mode of action of medical methods of abortion. J Am Med Womens Assoc. 2000. 55(3 Suppl):121-6. [Medline].

  43. Ballagh SA, Harris HA, Demasio K. Is curettage needed for uncomplicated incomplete spontaneous abortion?. Am J Obstet Gynecol. 1998 Nov. 179(5):1279-82. [Medline].

  44. Bartholomew LL, Grimes DA. The alleged association between induced abortion and risk of breast cancer: biology or bias?. Obstet Gynecol Surv. 1998 Nov. 53(11):708-14. [Medline].

  45. Begley AM. Preparation for practice in the new millennium: a discussion of the moral implications of multifetal pregnancy reduction. Nurs Ethics. 2000 Mar. 7(2):99-112. [Medline].

  46. Berer M. Making abortions safe: a matter of good public health policy and practice. Bull World Health Organ. 2000. 78(5):580-92. [Medline].

  47. Bernick BA, Ufberg DD, Nemiroff R, Donnenfeld A, Tolosa JE. Success rate of cytogenetic analysis at the time of second-trimester dilation and evacuation. Am J Obstet Gynecol. 1998 Oct. 179(4):957-61. [Medline].

  48. Bernstein PS, Rosenfield A. Abortion and maternal health. Int J Gynaecol Obstet. 1998 Dec. 63 Suppl 1:S115-22. [Medline].

  49. Blanchard K, Winikoff B, Ellertson C. Misoprostol used alone for the termination of early pregnancy. A review of the evidence. Contraception. 1999 Apr. 59(4):209-17. [Medline].

  50. Borgatta L, Burnhill M, Haskell S, Nichols M, Leonhardt K. Instituting medical abortion services: changes in outcome and acceptability related to provider experience. J Am Med Womens Assoc. 2000. 55(3 Suppl):173-6. [Medline].

  51. Borgatta L, Chen AY, Reid SK, Stubblefield PG, Christensen DD, Rashbaum WK. Pelvic embolization for treatment of hemorrhage related to spontaneous and induced abortion. Am J Obstet Gynecol. 2001 Sep. 185(3):530-6. [Medline].

  52. Borgmann CE, Jones BS. Legal issues in the provision of medical abortion. Am J Obstet Gynecol. 2000 Aug. 183(2 Suppl):S84-94. [Medline].

  53. Bourguignon A, Briscoe B, Nemzer L. Genetic abortion: considerations for patient care. J Perinat Neonatal Nurs. 1999 Sep. 13(2):47-58. [Medline].

  54. Breitbart V, Repass DC. The counseling component of medical abortion. J Am Med Womens Assoc. 2000. 55(3 Suppl):164-6. [Medline].

  55. Cakir L, Dilbaz B, Caliskan E, Dede FS, Dilbaz S, Haberal A. Comparison of oral and vaginal misoprostol for cervical ripening before manual vacuum aspiration of first trimester pregnancy under local anesthesia: a randomized placebo-controlled study. Contraception. 2005 May. 71(5):337-42. [Medline].

  56. Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertil Steril. 1986 Jan. 45(1):5-17. [Medline].

  57. Cates W, Ellertson C. Contraceptive Technology. Hatcher RA, Trussel J, Stewart F, et al. Abortion. 17th ed. New York, NY: Ardent Media; 1998. 682-697.

  58. Chapman SJ, Crispens M, Owen J, Savage K. Complications of midtrimester pregnancy termination: the effect of prior cesarean delivery. Am J Obstet Gynecol. 1996 Oct. 175(4 Pt 1):889-92. [Medline].

  59. Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. N Engl J Med. 2000 Mar 30. 342(13):946-56. [Medline].

  60. Chung TK, Lee DT, Cheung LP, Haines CJ, Chang AM. Spontaneous abortion: a randomized, controlled trial comparing surgical evacuation with conservative management using misoprostol. Fertil Steril. 1999 Jun. 71(6):1054-9. [Medline].

  61. Clark S, Ellertson C, Winikoff B. Is medical abortion acceptable to all American women: the impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion. J Am Med Womens Assoc. 2000. 55(3 Suppl):177-82. [Medline].

  62. Cohen AL, Bhatnagar J, Reagan S, et al. Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion. Obstet Gynecol. 2007 Nov. 110(5):1027-33. [Medline].

  63. Cole DS, Bruck LR. Anaphylaxis after laminaria insertion. Obstet Gynecol. 2000 Jun. 95(6 Pt 2):1025. [Medline].

  64. Collins MK, Moreau JF, Opel D, et al. Compliance with pregnancy prevention measures during isotretinoin therapy. J Am Acad Dermatol. 2014 Jan. 70(1):55-9. [Medline].

  65. Cook RJ, Dickens BM. Human rights and abortion laws. Int J Gynaecol Obstet. 1999 Apr. 65(1):81-7. [Medline].

  66. Coyaji K. Early medical abortion in India: three studies and their implications for abortion services. J Am Med Womens Assoc. 2000. 55(3 Suppl):191-4. [Medline].

  67. Creinin MD. Conception rates after abortion with methotrexate and misoprostol. Int J Gynaecol Obstet. 1999 May. 65(2):183-8. [Medline].

  68. Creinin MD. Medical abortion regimens: historical context and overview. Am J Obstet Gynecol. 2000 Aug. 183(2 Suppl):S3-9. [Medline].

  69. Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol. 2004 May. 103(5 Pt 1):851-9. [Medline].

  70. Creinin MD, Jerald H. Success rates and estimation of gestational age for medical abortion vary with transvaginal ultrasonographic criteria. Am J Obstet Gynecol. 1999 Jan. 180(1 Pt 1):35-41. [Medline].

  71. Creinin MD, Pymar HC. Medical abortion alternatives to mifepristone. J Am Med Womens Assoc. 2000. 55(3 Suppl):127-32, 150. [Medline].

  72. Creinin MD, Spitz IM. Use of various ultrasonographic criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion. Am J Obstet Gynecol. 1999 Dec. 181(6):1419-24. [Medline].

  73. Creinin MD, Wiebe E, Gold M. Methotrexate and misoprostol for early abortion in adolescent women. J Pediatr Adolesc Gynecol. 1999 May. 12(2):71-7. [Medline].

  74. Daling JR, Emanuel I. Induced abortion and subsequent outcome of pregnancy. A matched cohort study. Lancet. 1975 Jul 26. 2(7926):170-3. [Medline].

  75. Davis A, Westhoff C, De Nonno L. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. J Am Med Womens Assoc. 2000. 55(3 Suppl):141-4. [Medline].

  76. Dean G, Cardenas L, Darney P, Goldberg A. Acceptability of manual versus electric aspiration for first trimester abortion: a randomized trial. Contraception. 2003 Mar. 67(3):201-6. [Medline].

  77. Delfs E, Katayama KP. Surgical Management of Reproductive Failure and Abortion. Te Linde's Operative Gynecology. Fifth Edition. 1977. 429-451.

  78. Dobie SA, Hart LG, Glusker A, Madigan D, Larson EH, Rosenblatt RA. Abortion services in rural Washington State, 1983-1984 to 1993-1994: availability and outcomes. Fam Plann Perspect. 1999 Sep-Oct. 31(5):241-5. [Medline].

  79. Drey EA, Thomas LJ, Benowitz NL, Goldschlager N, Darney PD. Safety of intra-amniotic digoxin administration before late second-trimester abortion by dilation and evacuation. Am J Obstet Gynecol. 2000 May. 182(5):1063-6. [Medline].

  80. Edmondson AS, Cooke EM. The development and assessment of a bacteriocin typing method for Klebsiella. J Hyg (Lond). 1979 Apr. 82(2):207-23. [Medline].

  81. Elimian A, Verma U, Tejani N. Effect of causing fetal cardiac asystole on second-trimester abortion. Obstet Gynecol. 1999 Jul. 94(1):139-41. [Medline].

  82. Elul B, Ellertson C, Winikoff B, Coyaji K. Side effects of mifepristone-misoprostol abortion versus surgical abortion. Data from a trial in China, Cuba, and India. Contraception. 1999 Feb. 59(2):107-14. [Medline].

  83. Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. J Am Med Womens Assoc. 2000. 55(3 Suppl):169-72. [Medline].

  84. Epner JE, Jonas HS, Seckinger DL. Late-term abortion. JAMA. 1998 Aug 26. 280(8):724-9. [Medline].

  85. Evans MI, Goldberg JD, Horenstein J, et al. Selective termination for structural, chromosomal, and mendelian anomalies: international experience. Am J Obstet Gynecol. 1999 Oct. 181(4):893-7. [Medline].

  86. Fitzpatrick KM, Wilson M. Exposure to violence and posttraumatic stress symptomatology among abortion clinic workers. J Trauma Stress. 1999 Apr. 12(2):227-42. [Medline].

  87. Fong YF, Singh K, Prasad RN. Severe hyperthermia following use of vaginal misoprostol for pre-operative cervical priming. Int J Gynaecol Obstet. 1999 Jan. 64(1):73-4. [Medline].

  88. Frank PI, McNamee R, Hannaford PC, Kay CR, Hirsch S. The effect of induced abortion on subsequent pregnancy outcome. Br J Obstet Gynaecol. 1991 Oct. 98(10):1015-24. [Medline].

  89. Gerhardt A, Zotz RB, Stockschlaeder M, Scharf RE. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb Haemost. 2007 Mar. 97(3):496-7. [Medline].

  90. Geva E, Fait G, Yovel I, et al. Second-trimester multifetal pregnancy reduction facilitates prenatal diagnosis before the procedure. Fertil Steril. 2000 Mar. 73(3):505-8. [Medline].

  91. Gouk EV, Lincoln K, Khair A, Haslock J, Knight J, Cruickshank DJ. Medical termination of pregnancy at 63 to 83 days gestation. Br J Obstet Gynaecol. 1999 Jun. 106(6):535-9. [Medline].

  92. Grimes D, Schulz K, Stanwood N. Immediate post-abortal insertion of intrauterine devices. Cochrane Database Syst Rev. 2000. CD001777. [Medline].

  93. Grimes DA. A 26-year-old woman seeking an abortion. JAMA. 1999 Sep 22-29. 282(12):1169-75. [Medline].

  94. Grimes DA. The continuing need for late abortions. JAMA. 1998 Aug 26. 280(8):747-50. [Medline].

  95. Grimes DA. Unsafe abortion: the silent scourge. Br Med Bull. 2003. 67:99-113. [Medline].

  96. Grimes DA, Schulz KF. Morbidity and mortality from second-trimester abortions. J Reprod Med. 1985 Jul. 30(7):505-14. [Medline].

  97. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG. 2005 Aug. 112(8):1102-8. [Medline].

  98. Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 64 to 91 days of gestation: a review of 483 consecutive cases. Am J Obstet Gynecol. 2003 May. 188(5):1315-9. [Medline].

  99. Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 9-13 weeks' gestation: a review of 1076 consecutive cases. Contraception. 2005 May. 71(5):327-32. [Medline].

  100. Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg. 2014 Jun. 18(6):797-806. [Medline].

  101. Heath V, Chadwick V, Cooke I, Manek S, MacKenzie IZ. Should tissue from pregnancy termination and uterine evacuation routinely be examined histologically?. BJOG. 2000 Jun. 107(6):727-30. [Medline].

  102. Hellberg D, Mogilevkina I, Mardh PA. Sexually transmitted diseases and gynecologic symptoms and signs in women with a history of induced abortion. Sex Transm Dis. 1999 Apr. 26(4):197-200. [Medline].

  103. Henshaw SK. Abortion incidence and services in the United States, 1995-1996. Fam Plann Perspect. 1998 Nov-Dec. 30(6):263-70, 287. [Medline].

  104. Hern WM. Second-trimester surgical abortions. Sciarra JJ. Gynecology and Obstetrics. Philadelphia, PA: JB Lippincott Co; 2002.

  105. Isley MM, Blumenthal P. Medical Abortion What's Old, what's new?. Contemporary OB GYN. 2008 Apr 15. 30-38.

  106. Jackson RA, Teplin VL, Drey EA, Thomas LJ, Darney PD. Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. Obstet Gynecol. 2001 Mar. 97(3):471-6. [Medline].

  107. Jain JK, Kuo J, Mishell DR Jr. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Obstet Gynecol. 1999 Apr. 93(4):571-5. [Medline].

  108. Jain JK, Meckstroth KR, Mishell DR Jr. Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. Am J Obstet Gynecol. 1999 Dec. 181(6):1386-91. [Medline].

  109. Jain JK, Meckstroth KR, Park M, Mishell DR Jr. A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception. 1999 Dec. 60(6):353-6. [Medline].

  110. Jensen JT, Harvey SM, Beckman LJ. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. Am J Obstet Gynecol. 2000 Jun. 182(6):1292-9. [Medline].

  111. Jensen MP, Miller L, Fisher LD. Assessment of pain during medical procedures: a comparison of three scales. Clin J Pain. 1998 Dec. 14(4):343-9. [Medline].

  112. Jermy K, Oyelese O, Bourne T. Uterine anomalies and failed surgical termination of pregnancy: the role of routine preoperative transvaginal sonography. Ultrasound Obstet Gynecol. 1999 Dec. 14(6):431-3. [Medline].

  113. Jones BS, Heller S. Providing medical abortion: legal issues of relevance to providers. J Am Med Womens Assoc. 2000. 55(3 Suppl):145-50. [Medline].

  114. Joyce T, Kaestner R. The impact of Mississippi's mandatory delay law on the timing of abortion. Fam Plann Perspect. 2000 Jan-Feb. 32(1):4-13. [Medline].

  115. Kafrissen ME, Grimes DA, Hogue CJ, Sacks JJ. Cluster of abortion deaths at a single facility. Obstet Gynecol. 1986 Sep. 68(3):387-9. [Medline].

  116. Kalish RB, Chasen ST, Rosenzweig LB, Rashbaum WK, Chervenak FA. Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome. Am J Obstet Gynecol. 2002 Oct. 187(4):882-5. [Medline].

  117. Keder LM. Best practices in surgical abortion. Am J Obstet Gynecol. 2003 Aug. 189(2):418-22. [Medline].

  118. Kero A, Hogberg U, Lalos A. Wellbeing and mental growth-long-term effects of legal abortion. Soc Sci Med. 2004 Jun. 58(12):2559-69. [Medline].

  119. Kero A. Wellbeing and mental growth - long term effects of legal abortion.

  120. Kjems E, Krag C. Melanoma and pregnancy. A review. Acta Oncol. 1993. 32(4):371-8. [Medline].

  121. Koonin LM. Abortion reporting in the era of medical procedures: why is it important?. J Am Med Womens Assoc. 2000. 55(3 Suppl):203-4. [Medline].

  122. Kruse B. Advanced practice clinicians and medical abortion: increasing access to care. J Am Med Womens Assoc. 2000. 55(3 Suppl):167-8. [Medline].

  123. Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol. 2000 Aug. 183(2 Suppl):S65-75. [Medline].

  124. Lagan BM, Dolk H, White B, Uges DR, Sinclair M. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies. Pharmacoepidemiol Drug Saf. 2014 Apr. 23(4):411-8. [Medline]. [Full Text].

  125. Lahteenmaki P, Luukkainen T. Return of ovarian function after abortion. Clin Endocrinol (Oxf). 1978 Feb. 8(2):123-32. [Medline].

  126. Larsson PG, Platz-Christensen JJ, Dalaker K, et al. Treatment with 2% clindamycin vaginal cream prior to first trimester surgical abortion to reduce signs of postoperative infection: a prospective, double-blinded, placebo-controlled, multicenter study. Acta Obstet Gynecol Scand. 2000 May. 79(5):390-6. [Medline].

  127. Lazovich D, Thompson JA, Mink PJ, Sellers TA, Anderson KE. Induced abortion and breast cancer risk. Epidemiology. 2000 Jan. 11(1):76-80. [Medline].

  128. Levgur M, Abadi MA, Tucker A. Adenomyosis: symptoms, histology, and pregnancy terminations. Obstet Gynecol. 2000 May. 95(5):688-91. [Medline].

  129. Lichtenberg ES, Shott S. A randomized clinical trial of prophylaxis for vacuum abortion: 3 versus 7 days of doxycycline. Obstet Gynecol. 2003 Apr. 101(4):726-31. [Medline].

  130. Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield PG, Ryan KJ. The relationship between induced abortion and outcome of subsequent pregnancies. Am J Obstet Gynecol. 1983 May 15. 146(2):136-40. [Medline].

  131. Lokeland M, Iversen OE, Dahle GS, Nappen MH, Ertzeid L, Bjorge L. Medical abortion at 63 to 90 days of gestation. Obstet Gynecol. 2010 May. 115(5):962-8. [Medline].

  132. Macisaac L, Darney P. Early surgical abortion: an alternative to and backup for medical abortion. Am J Obstet Gynecol. 2000 Aug. 183(2 Suppl):S76-83. [Medline].

  133. MacIsaac L, Grossman D, Balistreri E, Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol. 1999 May. 93(5 Pt 1):766-70. [Medline].

  134. Major B, Gramzow RH. Abortion as stigma: cognitive and emotional implications of concealment. J Pers Soc Psychol. 1999 Oct. 77(4):735-45. [Medline].

  135. Mansfield C, Hopfer S, Marteau TM. Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. European Concerted Action: DADA (Decision-making After the Diagnosis of a fetal Abnormality). Prenat Diagn. 1999 Sep. 19(9):808-12. [Medline].

  136. Martin CW, Brown AH, Baird DT. A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary. Contraception. 1998 Aug. 58(2):99-103. [Medline].

  137. Mayr NA, Wen BC, Saw CB. Radiation therapy during pregnancy. Obstet Gynecol Clin North Am. 1998 Jun. 25(2):301-21. [Medline].

  138. Mcfarlane DR. Induced abortion: an historical overview. Am J Gynecol Health. 1993 May-Jun. 7(3):77-82. [Medline].

  139. Medich DS, Fazio VW. Hemorrhoids, anal fissure, and carcinoma of the colon, rectum, and anus during pregnancy. Surg Clin North Am. 1995 Feb. 75(1):77-88. [Medline].

  140. Miller VL, Ransom SB, Shalhoub A, Sokol RJ, Evans MI. Multifetal pregnancy reduction: perinatal and fiscal outcomes. Am J Obstet Gynecol. 2000 Jun. 182(6):1575-80. [Medline].

  141. Nielsen S, Hahlin M, Platz-Christensen J. Randomised trial comparing expectant with medical management for first trimester miscarriages. Br J Obstet Gynaecol. 1999 Aug. 106(8):804-7. [Medline].

  142. Oteri O, Hopkins R. Second trimester therapeutic abortion using mifepristone and oral misoprostol in a woman with two previous caesarean sections and a cone biopsy. J Matern Fetal Med. 1999 Nov-Dec. 8(6):300-1. [Medline].

  143. Owen J, Hauth JC. Vaginal misoprostol vs. concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination. J Matern Fetal Med. 1999 Mar-Apr. 8(2):48-50. [Medline].

  144. Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception. 2003 Jul. 68(1):31-4. [Medline].

  145. Papiernik E, Grange G, Zeitlin J. Should multifetal pregnancy reduction be used for prevention of preterm deliveries in triplet or higher order multiple pregnancies?. J Perinat Med. 1998. 26(5):365-70. [Medline].

  146. Paul M. Office management of early induced abortion. Clin Obstet Gynecol. 1999 Jun. 42(2):290-305. [Medline].

  147. Paul M, Lichtenberg ES, Borgatta L. A Clinician's Guide to Medical and Surgical Abortion. New York, NY: Churchill Livingstone; 1999.

  148. Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. Am J Obstet Gynecol. 2000 Aug. 183(2 Suppl):S34-43. [Medline].

  149. Paul ME, Mitchell CM, Rogers AJ, Fox MC, Lackie EG. Early surgical abortion: efficacy and safety. Am J Obstet Gynecol. 2002 Aug. 187(2):407-11. [Medline].

  150. Penfield AJ. Gynecologic Surgery Under Local Anesthesia. Baltimore, Md: Urban & Schwarzenburg; 1986. 65-94.

  151. Perry KG Jr, Rinehart BK, Terrone DA, Martin RW, May WL, Roberts WE. Second-trimester uterine evacuation: A comparison of intra-amniotic (15S)-15-methyl-prostaglandin F2alpha and intravaginal misoprostol. Am J Obstet Gynecol. 1999 Nov. 181(5 Pt 1):1057-61. [Medline].

  152. Pope LM, Adler NE, Tschann JM. Postabortion psychological adjustment: are minors at increased risk?. J Adolesc Health. 2001 Jul. 29(1):2-11. [Medline].

  153. Reeves MF, Lohr PA, Harwood BJ, Creinin MD. Ultrasonographic endometrial thickness after medical and surgical management of early pregnancy failure. Obstet Gynecol. 2008 Jan. 111(1):106-12. [Medline].

  154. Rosenblatt RA, Robinson KB, Larson EH, Dobie SA. Medical students' attitudes toward abortion and other reproductive health services. Fam Med. 1999 Mar. 31(3):195-9. [Medline].

  155. Sandstrom O, Brooks L, Schantz A, Grinsted J, Grinsted L, Jacobsen JD. Interruption of early pregnancy with mifepristone in combination with gemeprost. Acta Obstet Gynecol Scand. 1999 Oct. 78(9):806-9. [Medline].

  156. Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol. 1996 May. 87(5 Pt 2):884-90. [Medline].

  157. Schaff EA, Fielding SL. A comparison of the Abortion Rights Mobilization and Population Council trials. J Am Med Womens Assoc. 2000. 55(3 Suppl):137-40. [Medline].

  158. Schaff EA, Fielding SL, Eisinger SH, Stadalius LS, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception. 2000 Jan. 61(1):41-6. [Medline].

  159. Schaff EA, Fielding SL, Westhoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMA. 2000 Oct 18. 284(15):1948-53. [Medline].

  160. Schüler L, Pastuszak A, Sanseverino TV, et al. Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol. 1999 Mar-Apr. 13(2):147-51. [Medline].

  161. Selam B, Lembet A, Stone J, Lapinski R, Berkowitz RL. Pregnancy complications and neonatal outcomes in multifetal pregnancies reduced to twins compared with nonreduced twin pregnancies. Am J Perinatol. 1999. 16(2):65-71. [Medline].

  162. Selam B, Torok O, Lembet A, Stone J, Lapinski R, Berkowitz RL. Genetic amniocentesis after multifetal pregnancy reduction. Am J Obstet Gynecol. 1999 Jan. 180(1 Pt 1):226-30. [Medline].

  163. Singh K, Ratnam SS. The influence of abortion legislation on maternal mortality. Int J Gynaecol Obstet. 1998 Dec. 63 Suppl 1:S123-9.

  164. Sorosky JI, Scott-Conner CE. Breast disease complicating pregnancy. Obstet Gynecol Clin North Am. 1998 Jun. 25(2):353-63. [Medline].

  165. Stephen JA, Timor-Tritsch IE, Lerner JP, Monteagudo A, Alonso CM. Amniocentesis after multifetal pregnancy reduction: is it safe?. Am J Obstet Gynecol. 2000 Apr. 182(4):962-5. [Medline].

  166. Stotland NL. The myth of the abortion trauma syndrome. JAMA. 1992 Oct 21. 268(15):2078-9. [Medline].

  167. Strauss LT, Herndon J, Chang J, Parker WY, Levy DA, Bowens SB. Abortion surveillance--United States, 2001. MMWR Surveill Summ. 2004 Nov 26. 53(9):1-32. [Medline].

  168. Trussell J, Ellertson C. Estimating the efficacy of medical abortion. Contraception. 1999 Sep. 60(3):119-35. [Medline].

  169. US Government Printing Office, Washington DC. Partial-Birth Abortion Ban Act of 2003.

  170. Ventura SJ, Mosher WD, Curtin SC, Abma JC, Henshaw S. Trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976-96. Vital Health Stat 21. 2000 Jan. (56):1-47. [Medline].

  171. Vintzileos AM, Ananth CV, Smulian JC, Beazoglou T, Knuppel RA. Routine second-trimester ultrasonography in the United States: a cost-benefit analysis. Am J Obstet Gynecol. 2000 Mar. 182(3):655-60. [Medline].

  172. Westfall JM, Sophocles A, Burggraf H, Ellis S. Manual vacuum aspiration for first-trimester abortion. Arch Fam Med. 1998 Nov-Dec. 7(6):559-62. [Medline].

  173. Wiebe E, Guilbert E, Jacot F, Shannon C, Winikoff B. A fatal case of Clostridium sordellii septic shock syndrome associated with medical abortion. Obstet Gynecol. 2004 Nov. 104(5 Pt 2):1142-4. [Medline].

  174. Wiebe ER. Comparing abortion induced with methotrexate and misoprostol to methotrexate alone. Contraception. 1999 Jan. 59(1):7-10. [Medline].

  175. Wiebe ER. Tamoxifen compared to methotrexate when used with misoprostol for abortion. Contraception. 1999 Apr. 59(4):265-70. [Medline].

  176. World Health Organization. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. BJOG. 2000 Apr. 107(4):524-30. [Medline].

  177. Wu S. Medical abortion in China. J Am Med Womens Assoc. 2000. 55(3 Suppl):197-9, 204. [Medline].

  178. Borgatta L, Kapp N, Society of Family Planning. Clinical guidelines. Labor induction abortion in the second trimester. Contraception. 2011 Jul. 84 (1):4-18. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.